Switch to:
Repros Therapeutics Inc (NAS:RPRX)
EV/EBITDA
-1.14 (As of Today)

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Repros Therapeutics Inc's enterprise value is $28.94 Mil. Repros Therapeutics Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Mar. 2016 was $-25.50 Mil. Therefore, Repros Therapeutics Inc's EV/EBITDA ratio for today is -1.14.

RPRX' s EV/EBITDA Range Over the Past 10 Years
Min: -31.5   Max: -0.2
Current: -1.14

-31.5
-0.2

During the past 13 years, the highest EV/EBITDA Ratio of Repros Therapeutics Inc was -0.20. The lowest was -31.50. And the median was -7.65.

RPRX's EV/EBITDA is ranked lower than
99.99% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. RPRX: -1.14 )

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

As of today, Repros Therapeutics Inc's stock price is $1.85. Repros Therapeutics Inc's earnings per share for the trailing twelve months (TTM) ended in Mar. 2016 was $-1.05. Therefore, Repros Therapeutics Inc's P/E Ratio for today is .

The "classic" EV/EBITDA ratio is much better in capturing debt and net cash than the P/E Ratio.


Definition

Repros Therapeutics Inc's EV/EBITDA for today is calculated as:

EV/EBITDA=Enterprise Value (Today)/Earnings Before Depreciation and Amortization (TTM)
=28.943/-25.495
=-1.14

Repros Therapeutics Inc's current Enterprise Value is $28.94 Mil.
Repros Therapeutics Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Mar. 2016 was -7.783 (Jun. 2015 ) + -6.602 (Sep. 2015 ) + -6.268 (Dec. 2015 ) + -4.842 (Mar. 2016 ) = $-25.50 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

Repros Therapeutics Inc's P/E Ratio for today is calculated as:

P/E Ratio=Share Price (Today)/Earnings Per Share (TTM)
=1.85/-1.048
=

Repros Therapeutics Inc's share price for today is $1.85.
Repros Therapeutics Inc's Earnings Per Share for the trailing twelve months (TTM) ended in Mar. 2016 was -0.32 (Jun. 2015 ) + -0.27 (Sep. 2015 ) + -0.258 (Dec. 2015 ) + -0.2 (Mar. 2016 ) = $-1.05.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Study has found that the companies with the lowest EV/EBITDA outperforms companies measured as cheap by other ratios such as P/E Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Related Terms

Enterprise Value, Earnings Before Depreciation and Amortization, P/E Ratio


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Repros Therapeutics Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
ev2ebitda -8.65-6.45-5.63-0.68-5.17-4.44-13.65-12.57-6.06-0.28

Repros Therapeutics Inc Quarterly Data

Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16
ev2ebitda -12.57-11.94-11.28-5.87-6.06-5.29-4.49-5.02-0.28-0.30
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK